Core Insights - The company reported a strong third quarter with year-to-date revenue growth of 11% and EPS growth of 15%, indicating robust performance across various global markets and business segments [1] - Despite the strong performance, the company has chosen not to upgrade its guidance due to uncertainties regarding potential headwinds, including the timing of product transitions in China and tender risks in Latin America [2] Strategic Relationships - The company has made significant progress in building a relationship with the U.S. government, particularly under President Trump's administration, focusing on understanding the changing global landscape [3][4] - The company is aligning its strategy with the U.S. administration's goals, which include rebalancing the costs and risks of innovation in the pharmaceutical industry, ensuring that wealthy countries contribute fairly to the development of new medicines [4][5] Pricing and Market Strategy - The company has agreed to reduce prices for Medicaid in the U.S. as part of its commitment to provide immediate relief to disadvantaged patients, while also planning to equalize prices for new products across wealthy countries in the future [7][8] - The company believes it can absorb the impact of these pricing adjustments without affecting its growth momentum or long-term ambitions, indicating a strong geographical footprint and a robust portfolio of new products [10][11]